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Abstract
The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to
consider in this revision 2 of Flavouring Group Evaluation 201, the additional data on genotoxicity
submitted by the Industry on two substances, 2-methylpent-2-enal [FL-no: 05.090] and 2
methylcrotonaldehyde [FL-no: 05.095], from subgroup 1.1.2 of FGE.19. In FGE.201Rev1, the
Panel concluded that further data were required in order to clarify the genotoxic potential of this
subgroup and considered the testing of 2-methylcrotonaldehyde [FL-no: 05.095] in a comet assay in
liver and duodenum, the first site of contact, as a preferred option to further investigate the
genotoxicity in vivo. New genotoxicity studies have been submitted for both 2-methylpent-2-enal [FL-
no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095]. 2-Methylpent-2-enal [FL-no: 05.090] tested
in a combined micronucleus/comet assay did not induce DNA damage, overruling the weak gene
mutation effect observed in bacteria and confirming the negative results observed in the in vitro
micronucleus assay. 2-Methylcrotonaldehyde [FL-no: 05.095] did not induce gene mutations in liver
and glandular stomach of transgenic rats. In addition, 2-methylcrotonaldehyde [FL-no: 05.095] tested
in an in vivo comet assay in liver and duodenum, it did not induce DNA damage. Overall, the
Panel concluded that the genotoxic evidence observed in vitro, was not confirmed in vivo for the
representative substances 2-methylcrotonaldehyde [FL-no: 05.095] and 2-methylpent-2-enal [FL-no:
05.090], therefore all the 10 substances in this subgroup [FL-no: 02.174, 05.033, 05.090, 05.095,
05.105, 05.107, 05.126, 07.261, 12.065 and 12.079] can be evaluated through the Procedure for the
evaluation of flavouring substances.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: a,b-unsaturated aldehydes, 2-alkylated substances, FGE.201, FGE.19, subgroup 1.1.2
Requestor: European Commission
Question numbers: EFSA-Q-2017-00117, EFSA-Q-2017-00118, EFSA-Q-2017-00119, EFSA-Q-2017-




Panel members: Gabriele Aquilina, Laurence Castle, Karl-Heinz Engel, Paul Fowler, Maria Jose Frutos
Fernandez, Peter F€urst, Rainer G€urtler, Ursula Gundert-Remy, Trine Husøy, Wim Mennes, Peter Moldeus,
Agneta Oskarsson, Sandra Rainieri, Romina Shah, Ine Waalkens-Berendsen, Detlef W€olfle and Maged
Younes.
Acknowledgements: The Panel wishes to thank the hearing experts: Vibe Beltoft and Karin Nørby
for the support provided to this scientific opinion.
Suggested citation: EFSA FAF Panel (EFSA Panel on Food Additives and Flavourings), Younes M,
Aquilina G, Castle L, Engel K-H, Fowler P, Frutos Fernandez MJ, F€urst P, Gundert-Remy U, Husøy T,
Mennes W, Moldeus P, Oskarsson A, Rainieri S, Shah R, Waalkens-Berendsen I, W€olfle D, Binderup M-L,
Bolognesi C, Marcon F, Marzin D, Mosesso P, Anastassiadou M, Carfı M, Vianello G and G€urtler R, 2018.
Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2-alkylated, aliphatic,
acyclic alpha,beta-unsaturated aldehydes and precursors, with or without additional double-bonds,
from chemical subgroup 1.1.2 of FGE.19. EFSA Journal 2018;16(10):5423, 33 pp. https://doi.org/10.
2903/j.efsa.2018.5423
ISSN: 1831-4732
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modifications or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Flavouring Group Evaluation 201 Revision 2




1.1. Background and Terms of Reference as provided by the requestor.................................................. 4
1.1.1. Terms of Reference ..................................................................................................................... 4
2. Data and methodologies .............................................................................................................. 5
2.1. History of the evaluation of FGE.19 substances ............................................................................. 5
2.2. Presentation of the substances in flavouring group evaluation 201Rev2........................................... 6
2.3. History of the evaluation of the substances belonging to FGE.201................................................... 6
2.4. Data evaluated by the Panel in FGE.201........................................................................................ 7
2.4.1. (Q)SAR predictions ...................................................................................................................... 7
2.4.2. Carcinogenicity studies ................................................................................................................ 8
2.4.3. Genotoxicity studies..................................................................................................................... 8
2.4.4. Conclusion on genotoxicity........................................................................................................... 8
2.4.5. Conclusion .................................................................................................................................. 8
2.5. Additional genotoxicity data evaluated by the Panel in FGE.201Rev1 ............................................... 8
2.5.1. In Vitro Data............................................................................................................................... 8
2.5.1.1. Ames tests.................................................................................................................................. 8
2.5.1.2. In vitro Micronucleus assay .......................................................................................................... 10
2.5.1.3. In vitro chromosomal aberration assay.......................................................................................... 11
2.5.2. In vivo genotoxicity tests ............................................................................................................. 11
2.5.2.1. Micronucleus assay...................................................................................................................... 11
2.5.3. Discussion of the additional data .................................................................................................. 12
2.5.4. Conclusion .................................................................................................................................. 13
3. Assessment................................................................................................................................. 13
3.1. Additional data evaluated by the Panel in FGE.201Rev2.................................................................. 13
3.1.1. Stability and decomposition products ............................................................................................ 13
3.1.2. 2-Methylpent-2-enal [FL-no: 05.090] – in vivo combined micronucleus and comet assay................... 14
3.1.3. 2-Methylcrotonaldehyde [FL-no: 05.095] – in vivo combined gene mutation and micronucleus assay
in transgenic rats ........................................................................................................................ 15
3.1.4. 2-Methylcrotonaldehyde [FL-no: 05.095] - in vivo comet assay ....................................................... 16
3.2. Discussion .................................................................................................................................. 16
3.3. Conclusion .................................................................................................................................. 16
Documentation provided to EFSA .............................................................................................................. 17
References............................................................................................................................................... 18
Abbreviations ........................................................................................................................................... 18
Appendix A – Specification Summary of the Substances in the Flavouring Group Evaluation 201Rev2 ............. 20
Appendix B – Summary of safety evaluation applying the procedure ............................................................ 23
Appendix C – (Q)SAR predictions............................................................................................................... 25
Appendix D – Genotoxicity data evaluated in FGE.201Rev1.......................................................................... 27
Appendix E – Genotoxicity studies evaluated in FGE.201Rev2 ...................................................................... 33
Flavouring Group Evaluation 201 Revision 2
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2018;16(10):5423
1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The use of flavouring is regulated under Regulation (EC) No 1334/20081 of the European Parliament
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring properties
for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and approval are
required for flavouring substances.
The Union List of flavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list includes a number of flavouring substances for which the safety
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
The substances in this group were included in the Union list with a footnote 1 (under evaluation by
EFSA).
In its opinion about this subgroup of 2012, the EFSA Panel considered that the mutagenicity hazard
could not be cleared by the endpoints evaluated in the in vivo micronucleus assay submitted. The
Panel therefore conclude that further data were required in order to clarify the genotoxic potential of this
subgroup. The Panel considered the Comet assay with [FL-no: 05.095] as test material and performed on
liver, blood and first site of contact, as a preferred option to further investigate the genotoxicity in vivo.
The additional data submitted by the applicant consist essentially of:
• a transgenic mutation assay in combination with an in vivo micronucleus assay for the
substance 2-methylcrotonaldehyde [FL-no: 05.095];
• a combination of a Comet/micronucleus assay for the substance 2-methylpent-2-enal [FL-no:
05.090].
The Panel also considered in this opinion on FGE.201 rev.1 that the additional data on 2-
methylcrotonaldehyde [FL-no: 05.095] could also be considered representative for the following
substances: 2,8-dithianon-4-en-4-carboxaldehyde [FL-no: 12.065] and 2-(methylthiomethyl)but-2-enal
[FL-no: 12.079].
1.1.1. Terms of Reference
The European Commission requests the European Food Safety Authority (EFSA) to evaluate the new
information submitted on 2-methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no:
05.095] including also 2,8-dithianon-4-en-4-carboxaldehyde [FL-no: 12.065] and 2-(methylthiomethyl)
but-2-enal [FL-no: 12.079] and, depending on the outcome, proceed to the full evaluation of the
substances of this group listed in the table below, in accordance with Commission Regulation (EC)
No 1565/2000, within 9 months.
In case the genotoxic potential cannot be ruled out or the procedure cannot be applied, EFSA is
asked to characterise the hazards and also quantify the exposure.
As regards the substance 2,6-Dimethyl-2,5,7-octatriene-1-ol acetate ([FL-no: 09.931] CAS no
999999-91-4) the applicant indicate that it is included in this subgroup 1.1.2 of FGE19 (FGE.201).
However, this substance has been already evaluated by EFSA in FGE 207 and FGE 72 Rev.1 of 2013.
As regards substance 4-methyl-3-hepten-5-one ([FL-no: 07.261] CAS no 22319-31-9) EFSA
indicated in its opinion FGE.204 that ‘the 2-methyl substituted alpha, beta-unsaturated aldehydes in
FGE.201Rev1 can be considered as structurally related to it [FL-no: 07.261]. Thus the final conclusion
on [FL-no: 07.261] will be drawn based on the outcome of the evaluation of FGE.201Rev1’.
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and certain
food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
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2. Data and methodologies
2.1. History of the evaluation of FGE.19 substances
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register
being a,b-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl
substances via hydrolysis and/or oxidation (EFSA, 2008a).
The a,b-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA,
2008a). The Panel noted that there were limited genotoxicity data on these flavouring substances but
that positive genotoxicity studies were identified for some substances in the group.
The a,b-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a
(quantitative) structure-activity relationship ((Q)SAR) prediction of the genotoxicity of these substances
was undertaken considering a number of models that were available at that time (DEREKfW, TOPKAT,
DTU-NFI-MultiCASE Models and ISS-Local Models (Gry et al., 2007)).
The Panel noted that for most of these models internal and external validation has been performed,
but considered that the outcome of these validations was not always extensive enough to appreciate
the validity of the predictions of these models for these a,b-unsaturated carbonyls. Therefore, the
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided
not to take substances through the procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and
Netzeva, 2007a,b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and the
fact that there are available data on genotoxicity, in vitro and in vivo, as well as data on
carcinogenicity for several substances. Based on these data the Panel decided that 15 subgroups
(1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 2008b) could
not be evaluated through the Procedure due to concern with respect to genotoxicity. Corresponding to
these subgroups, 15 Flavouring Group Evaluations (FGEs) were established: FGE.200, 204, 205, 206,
207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225.
For 11 subgroups, the Panel decided, based on the available genotoxicity data and (Q)SAR
predictions, that a further scrutiny of the data should take place before requesting additional data
from the Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203,
210, 212, 213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218, it was
concluded that a genotoxic potential could be ruled out and accordingly these substances were
evaluated using the Procedure. For all or some of the substances in the remaining FGEs, FGE.201,
203, 210, 212, 213, 216, 217 and 220 the genotoxic potential could not be ruled out.
To ease the data retrieval of the large number of structurally related a,b-unsaturated substances in
the different subgroups for which additional data are requested, EFSA worked out a list of
representative substances for each subgroup (EFSA, 2008c). In selecting the representative
substances, expert judgement was applied. In each subgroup, the representative substances were
selected taken into account chain length, branched chain, lipophilicity and possible additional functional
groups. Likewise, an EFSA genotoxicity expert group has worked out a test strategy to be followed in
the data retrieval for these substances (EFSA, 2008b).
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The Flavouring Industry has been requested to submit additional genotoxicity data according to the
list of representative substances and test strategy for each subgroup.
The Flavouring Industry has now submitted additional data and the present FGE concerns the
evaluation of these data requested on genotoxicity.
2.2. Presentation of the substances in flavouring group evaluation
201Rev2
The FGE.201, originally, concerned 11 substances, which are presented in Appendix A, Table A.1.
The 11 substances correspond to subgroup 1.1.2 of FGE.19 (EFSA, 2008b). Eight of these substances
are aliphatic acyclic 2-alkylated a,b-unsaturated aldehydes with or without additional double bonds [FL-
no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.130 and 05.178] and three are precursors for
such aldehydes [FL-no: 02.174, 09.177 and 09.931].
A summary of their current evaluation status by the JECFA is given in Appendix B, Table B.1
(JECFA, 2004, 2007).
The a,b-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA,
2008b). Accordingly, the available data on genotoxic or carcinogenic activity for the eight aldehydes in
FGE.201 [FL-no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.130 and 05.178] and the two
aldehydes [non-Register substances, 2,6-dimethyl-2,5,7-octatrienal and 2-methyl-2-propenal, see
Table A.1] anticipated to be metabolism products formed from two of the three precursors in FGE.201
[FL-no: 02.174, 09.177 and 09.931], have been considered in FGE.201. The anticipated metabolism
product formed from the third precursor [FL-no: 02.174] is one of the eight Register aldehydes in this
FGE [FL-no: 05.095].
The Panel has also taken into consideration the outcome of the predictions from five selected (Q)
SAR models (Benigni and Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) on the 10 aldehydes
[FL-no: 05.033, 05.090, 05.095, 05.105, 05.107, 05.126, 05.130, 05.178, 2-methyl-2-propenal and
2,6-dimethyl-2,5,7-octatrienal]. The 10 aldehydes and their (Q)SAR predictions are shown in
Appendix C Table C.1.
After the publication of FGE.201, Industry withdrew their wish of maintaining three of the
substances for use as flavours in EU, [FL-no: 05.130, 05.178 and 09.177]. One substance, [FL-no:
09.931], was evaluated in FGE.207 (EFSA CEF Panel, 2013) where the genotoxicity concern was ruled
out. In FGE.204 (EFSA CEF Panel, 2012a), the Panel noted that 2-methyl substituted a,b-unsaturated
aldehydes in FGE.201 can be considered as structurally related to 4-methyl-3-hepten-5-one [FL-no:
07.261]. Thus, the conclusion on [FL-no: 07.261] will be drawn based on the outcome of the
evaluation of FGE.201Rev2.
In FGE.201Rev1 (EFSA CEF Panel, 2012b), the Panel considered that additional data required for 2-
methylcrotonaldehyde [FL-no: 05.095] could also be considered representative for the substances in
FGE.225, 2,8-dithianon-4-en-4-carboxaldehyde [FL-no: 12.065] and 2-(methylthiomethyl)but-2-enal
[FL-no: 12.079].
Therefore, substances evaluated in FGE.201Rev2 are [FL-no: 02.174, 05.033, 05.090, 05.095,
05.105, 05.107, 05.126, 07.261, 12.065 and 12.079]. New genotoxicity data on [FL-no: 05.095] are
considered to cover the genotoxicity concern for the other nine substances [FL-no: 02.174, 05.033,
05.090, 05.105, 05.107, 05.126, 07.261, 12.065 and 12.079].
2.3. History of the evaluation of the substances belonging to FGE.201
In FGE.201 (EFSA, 2009), the Panel concluded that additional genotoxicity data were required for
all 11 a,b-unsaturated aldehydes and alcohols and related esters considered in the FGE.
In the EFSA Opinion ‘List of a,b-unsaturated aldehydes and ketones representative of FGE.19
substances for genotoxicity testing’ (EFSA, 2008c), representative flavouring substances have been
selected for subgroup 1.1.2, corresponding to FGE.201, for which additional data on genotoxicity were
requested, according to the Opinion of the Panel on the ‘Genotoxicity Test Strategy for Substances
Belonging to Subgroups of FGE.19’ (EFSA, 2008b) (see Table 1).
In reply to a data request presented in FGE.201, additional data were provided by Industry (EFFA,
2011) for the representative substance 2-methylpent-2-enal [FL-no: 05.090] and a non-representative
substance, also from subgroup 1.1.2, 2-methylcrotonaldehyde [FL-no: 05.095]. No data were
submitted for the other representatives identified by EFSA (EFSA, 2008c), beta-sinensal [FL-no:
05.178], 2-methyl-2-propenal (not a Register substance but a precursor for such) or its precursor
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2-methylallyl butyrate [FL-no: 09.177]. According to Industry, [FL-no: 05.178 and 09.177] are not any
longer supported by the Industry and accordingly no data were submitted for these substances due to
the lack of test material for the required genotoxicity testing. Also, alpha-sinensal [FL-no: 05.130] is
not any longer supported by the Industry. Data submitted were evaluated in FGE.201 Revision 1
(FGE.201Rev1).
In FGE.201Rev1 (EFSA CEF Panel, 2012b), the Panel concluded that there is some evidence for [FL-
no: 05.095] and an indication for [FL-no: 05.090] to show a potency for the induction of gene
mutations in vitro. Furthermore, the Panel considered that the mutagenicity hazard could not be
cleared by the endpoints evaluated in the in vivo micronucleus assay and that further data are
required in order to clarify the genotoxic potential of this subgroup. A comet assay performed with [FL-
no: 05.095] in liver, blood and first site of contact was considered as a preferred option to further
investigate the genotoxicity in vivo. Finally, the Panel concluded that the genotoxicity data for [FL-no:
05.095] could be representative for [FL-no: 02.174, 05.033, 05.090, 05.105, 05.107, 05.126, 07.261,
12.065 and 12.079] but not for the remaining substances of this subgroup [FL-no: 05.130, 05.178,
09.177 and 09.931], for which however, an evaluation by the Panel is not needed any longer.
In response to the requested genotoxicity data in FGE.201Rev1 on representative substances for
subgroup 1.1.2, new data on 2-methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no:
05.095] have been submitted by Industry that are evaluated in the present revision of FGE.201
(FGE.201Rev2).
The new data submitted for [FL-no: 05.090 and 05.095] are described and evaluated in Section 3
of the present revision FGE.201Rev2. Sections 2.4 and 2.5 report the same information that was
presented in FGE.201 (EFSA, 2009) and FGE.201Rev1 (EFSA CEF Panel, 2012b), respectively.
FGE Adopted by EFSA Link
No. of
Substances
FGE.201 25 September 2008 http://www.efsa.europa.eu/en/efsajournal/pub/1080 11
FGE.201Rev1 24 May 2012 http://www.efsa.europa.eu/en/efsajournal/pub/2749 11
FGE.201Rev2 13 September 2018 https://www.efsa.europa.eu/en/efsajournal/pub/5423 10
2.4. Data evaluated by the Panel in FGE.2014
2.4.1. (Q)SAR Predictions
In Appendix C Table C.1, the outcomes of the (Q)SAR predictions for possible genotoxicity activity
in five in vitro (Q)SAR models (ISS-Local Model-Ames Test, DTU-NFI-MultiCASE-Ames test,
-Chromosomal aberration test in Chinese hamster ovary cells (CHO), -Chromosomal aberration test in
Chinese hamster lung cells (CHL) and -Mouse Lymphoma Test) are presented. For the three short-
chain aldehydes [FL-no: 05.095, 05.090 and 05.105], the predictions in the ISS Local Ames test
Table 1: Representative substances for subgroup 1.1.2 of FGE.19 (EFSA, 2008c)
FL-no
JECFA-no
















Originally selected as representative substance













Originally selected as representative substance
Not supported by industry
4 The data presented in Section 2.4 are cited from the Scientific Opinion FGE.201. These data are the basis for the conclusions
in FGE.201 requesting additional genotoxicity data.
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(TA100) were positive. For 2-methyl-2-propenal, the DTU-NFI-MultiCASE Ames test was positive. All
other predictions were either negative or out of domain (See Table C.1).
2.4.2. Carcinogenicity studies
No carcinogenicity studies are available for the eight a,b-unsaturated aldehydes and the a,b-
unsaturated aldehydes anticipated to be formed from the three precursors [FL-no: 02.174, 09.177 and
09.931] in subgroup 1.1.2.
2.4.3. Genotoxicity studies
Only one study on 2-methylpent-2-enal [FL-no: 05.090] and one study on 2-methyl-2-propenal [not
in Register] is available for the eight aldehydes and the a,b-unsaturated aldehydes anticipated to be
formed from the precursors in subgroup 1.1.2. The study on 2-methylpent-2-enal is a spot test (Florin
et al., 1980), which is not in accordance with the OECD guideline. Furthermore, the methods and
results are insufficiently reported and the study is considered to be of insufficient validity. The study on
2-methyl-2-propenal (and the structurally related 2-propyl and 2-butyl substituted 2-propenals), in
Ames test in Salmonella Typhimurium strain TA100, showed mutagenic effects of all the 2-alkylated 2-
propenals (Eder and Deininger, 2001). The study was found valid. See Appendix D Table D.1.
2.4.4. Conclusion on genotoxicity
The genotoxicity concern with respect to this group of substances due to the presence of an a,b-
unsaturated aldehyde group (or precursor for this) cannot be ruled out based on the genotoxicity data
and (Q)SAR predictions available.
2.4.5. Conclusion
The Panel concluded that a genotoxic potential of the 11 a,b-unsaturated aldehydes and alcohols
and related esters in the present FGE.201 could not be ruled out. Accordingly the 11 substances
cannot be evaluated through the Procedure. Additional data on genotoxicity on substances
representative for this subgroup should be provided according to the Genotoxicity Test Strategy for
Substances Belonging to Subgroups of FGE.19 (EFSA, 2008b).
2.5. Additional genotoxicity data evaluated by the Panel in
FGE.201Rev15
2.5.1. In Vitro data
2.5.1.1. Ames tests
2-Methylpent-2-enal [FL-no: 05.090] was tested in S. Typhimurium strains TA98, TA100, TA102,
TA1535 and TA1537 in the presence and absence of metabolic activation by S-9 (Bowen, 2011). In the
first experiment performed using plate incorporation methodology, concentrations of 1.6, 8, 40, 200,
1,000 and 5,000 lg/plate were assessed for all tester strains. Evidence of toxicity was only observed in
strains TA1537 at 5,000 lg/plate in the presence of S-9 and TA102 at 1,000 lg/plate and above in the
presence of S-9. The concentration range was therefore narrowed for a second experiment. In addition,
the second experiment included a supplementary S-9 pre-incubation step for the S-9 treatment group to
increase the range of assay detection. Following these treatments, evidence of toxicity was observed in
the presence of S-9 in S. Typhimurium strains TA98, TA100, TA1535 and TA102 at 2,500 lg/plate and
above and in strain TA1537 at 1,250 lg/plate and above. Toxicity was not observed in the absence of
S-9. In the second experiment, at a single intermediate dose of 2,500 lg/plate without S-9 treatment in
strain TA1537, there was a small (2.1-fold), statistically significant increase in revertants, but this was
not dose-related and was within the range of historical controls. The Panel concluded that 2-methylpent-
2-enal was not mutagenic in this study (Tables D.1 and D.4).
A bacterial reverse mutation assay was also conducted in S. Typhimurium strains TA98, TA100,
TA1535, TA1537, and Escherichia coli strain WP2uvrA with 2-methylcrotonaldehyde [FL-no: 05.095]
(Nakajima, 2006a), which does not belong to the substances selected as representative by the
5 The data presented in Section 2.5 are cited from the Scientific Opinion FGE.201Rev1. These data are the basis for the
conclusions in FGE.201Rev1 requesting additional genotoxicity data.
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Panel for this subgroup. In an initial experiment, the concentrations used were 8.19, 20.5, 51.2, 128,
320, 800, 2,000 and 5,000 lg/plate. In strain TA100, 2-methylcrotonaldehyde increased the number of
colonies showing reverse mutations, both with and without metabolic activation by S-9, in a dose-
dependent manner. In the absence of S-9, the increases were threefold from 320 to 5,000 lg/plate,
and with S-9 metabolic activation, the increases were up to 3.9-fold from 320 to 2,000 lg/plate; under
these conditions, growth inhibition was observed at 5,000 lg/plate. In all other strains, in the
presence and absence of metabolic activation treatment with 2-methylcrotonaldehyde did not result in
an increase of reverse mutant colony (Tables D.1 and D.3).
In a second experiment using 2-methylcrotonaldehyde [FL-no: 05.095] concentrations of 156, 313,
625, 1,250, 2,500 and 5,000 lg/plate, treatment of strain TA100 in the absence of S-9 activation
induced a dose-dependent increase in reverse mutant colonies (1.5- to 7.2-fold), with growth inhibition
observed at 5,000 lg/plate in the absence of S-9. In the presence of S-9, treatment of strain TA100
also gave a dose-dependent (313–2,500 lg/plate) increase in reverse mutant colonies (1.2- to 4.6-
fold), with growth inhibition again observed at 5,000 lg/plate. In the absence of S-9, strain TA1535
gave a 1.8-fold increase in reverse mutants at 2,500 lg/plate, but this was not dose-dependent. Strain
TA98 had a nearly twofold increase in reverse mutant colonies in the absence of S-9 at both 2,500 and
5,000 lg/plate. These increases were above the historical control range but they were not clearly
dose-related. In the presence of S-9, the same strain showed a 1.5-fold increase at 5,000 lg/plate.
E. coli strain WP2uvrA showed a twofold increase in reverse mutant colonies at 5,000 lg/plate
treatment without S-9 which was above the historical control range, but otherwise there was no
increase at any other dose or with S-9 treatment (Tables D.1 and D.3).
Strain WP2uvrA did not show evidence of mutagenicity in the first experiment but produced weakly
mutagenic results in the second experiment at the highest concentration tested. Since the repeatability of
the result was not confirmed, an additional experiment with this strain was performed from 156 to
5,000 lg/plate and this resulted in a 1.4-fold increase in revertant colonies at 2,500 and 5,000 lg/plate.
The Panel considered these small increases as indication for a weak mutagenic potential because the
effects were reproducible in two out of three experiments and were above the historical control range.
However, with the exception of strain TA100, there were no increases in reverse mutation colonies
exceeding that of the negative control by twofold. The Panel considered that 2-methylcrotonaldehyde
[FL-no: 05.095] was mutagenic in the TA100 strain in the absence and presence of S-9 under the
specified conditions of the assay.
In order to clarify the ability of 2-methylcrotonaldehyde [FL-no: 05.095] to induce reverse mutations
and provide cross-laboratory comparison of results, a third Ames assay was conducted (Ballantyne,
2011) in the same laboratory in which the Bowen 2011 study was performed. In order to directly
compare 2-methylcrotonaldehyde with 2-methylpent-2-enal, the latter was tested additionally in this
assay. Both substances were tested in the single S. Typhimurium strain TA100, in the absence and the
presence of metabolic activation, in three separate experiments.
The first experiment was conducted using final concentrations of 2-methylcrotonaldehyde [FL-no:
05.095] and 2-methylpent-2-enal [FL-no: 05.090] at 1.6, 8, 40, 200, 1,000 and 5,000 lg/plate in
strain TA100 with or without S-9. Following these treatments, no evidence of toxicity was observed.
Statistically significant (p < 0.01) increases in revertants were observed for 2-methylcrotonaldehyde at
5,000 lg/plate in the absence of S-9 metabolic activation (1.3-fold) and at all concentrations tested in
the presence of S-9. In all cases, the increases were small versus concurrent controls (1.2- to 1.7-fold
vs concurrent controls) but were above the range of historical controls. Similarly, for 2-methylpent-2-
enal, small statistically significant (p < 0.05) increases in revertants (1.2-fold) were observed at
5,000 lg/plate in the absence of S-9 metabolic activation and at 1.6, 200 and 5,000 lg/plate
(p < 0.01) in the presence of S-9. In all cases, the increases were small versus concurrent controls
(1.2- to 1.4-fold vs concurrent controls) but the results obtained in the presence of S-9 were above
the range of historical controls and dose-related (Tables D.1 and D.5).
In the second experiment, treatment of strain TA100 with 2-methylcrotonaldehyde [FL-no: 05.095]
and 2-methylpent-2-enal [FL-no: 05.090] was performed in the absence and in the presence of S-9 at
narrowed concentration intervals. 2-Methylcrotonaldehyde and 2-methylpent-2-enal were assayed at
51.2, 128, 320, 800, 2,000 and 5,000 lg/plate in the absence of S-9 using plate incorporation
methodology and 8.192, 20.48, 51.2, 128, 320, 800, 2,000 and 5,000 lg/plate in the presence of S-9
using both plate incorporation and pre-incubation methodology. Clear evidence of toxicity was only
observed following pre-incubation methodology treatments with 2-methylcrotonaldehyde in the
presence of S-9 at 5,000 lg/plate and pre-incubation methodology treatments with 2-methylpent-2-
enal in the presence of S-9 at 2,000 and 5,000 lg/plate. In the absence of S-9 activation, small but
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statistically significant increases in revertant colonies showing a dose-dependent relationship were
observed for 2-methylcrotonaldehyde at 800, 2,000 and 5,000 lg/plate. These were only 1.3- to 1.4-
fold over concurrent vehicle controls but above the range of historical controls. In the presence of S-9
activation, 2-methylcrotonaldehyde showed a small but statistically significant increase in revertant
colonies only at 5,000 lg/plate using plate incorporation (1.4-fold) and at 800 and 2,000 lg/plate
using pre-incubation methodology (1.7-fold). These increases were above the historical control range.
Similarly, in the presence of S-9 activation 2-methylpent-2-enal showed a small (1.4-fold) but
statistically significant increase in revertants only at 5,000 lg/plate using plate incorporation
methodology, but in contrast gave no increases in revertant colonies using pre-incubation. In the
absence of S-9 activation, a statistically significant increase in revertant colonies was observed at
5,000 lg/plate that was 2.5-fold over concurrent vehicle controls. These increases were above the
historical control range, likewise (Tables D.1 and D.5).
In order to further investigate the reproducibility and dose relationship of some increases in
revertant numbers seen in the first two experiments, a third experiment was performed with
2-methylcrotonaldehyde [FL-no: 05.095] in the presence of S-9 (plate incorporation methodology only)
and with 2-methylpent-2-enal in the absence of S-9. In order to investigate the dose range over which
the increases in revertant numbers were previously observed, treatment concentration ranges of
0.32–5,000 lg/plate and 51.2–5,000 lg/plate were employed for 2-methylcrotonaldehyde and
2-methylpent-2-enal, respectively. Following these treatments, no evidence of toxicity was observed
with both substances. For 2-methylcrotonaldehyde, small (1.3- to 1.8-fold) but statistically significant
and dose-related increases in revertants were observed at 1,000 and 5,000 lg/plate. These increases
were above the historical control range. For 2-methylpent-2-enal, a small but statistically significant
increase in revertants was observed at 5,000 lg/plate. This increase was only 1.3-fold vs. concurrent
vehicle controls but above the historical control range.
Overall, statistically significant increases in revertant numbers (when the data were analysed at the
1% level using the Dunnett’s test) were observed in the absence and presence of S-9 in each experiment
where the TA100 strain was treated with 2-methylcrotonaldehyde [FL-no: 05.095]. These increases
provided evidence of a dose relationship, with the exception of the first experiment in the absence of S-9,
where the largest increase was observed at the lowest treatment concentration (1.6 lg/plate) and was
attributed to an aberrant occurrence that was not reproduced in subsequent experiments. While the
magnitude of these increases were small (1.3- to 1.8-fold above the concurrent control levels), these
data were considered by the authors of the study report as evidence of 2-methylcrotonaldehyde
mutagenic activity in strain TA100 in the absence and presence of metabolic activation with S-9. The
Panel noted that these increases, although being small, were above the range of historical controls and
that these effects were generally reproducible in the different experiments of this study. Thus, the
Panel concluded that this study provided an indication for a weak mutagenic activity of
2-methylcrotonaldehyde [FL-no: 05.095] in the presence and absence of metabolic activation.
2-Methylpent-2-enal [FL-no: 05.090] treatments of strain TA100 in the absence and presence of
S-9, assayed simultaneously for comparison to 2-methylcrotonaldehyde, resulted in statistically
significant increases in revertant numbers in the absence and presence of S-9 in each experiment, with
the exception of experiment 2 using pre-incubation methodology in the presence of S-9. The
maximum treatment concentration in the experiment 2 in the absence of S-9 resulted in a statistically
significant increase of 2.5-fold over the concurrent control level, though this was not reproduced in
experiments 1 or 3, nor previously observed (Bowen, 2011). However, the small increases observed in
experiments 1 and 3 were statistically significant and above the range of historical controls. Thus,
there is at least some consistency in these three experiments. The authors of the study report
(Ballantyne, 2011) noted that all of the observed increases provided at least some evidence of dose
dependence (in most cases the only responding concentration being the highest treatment
concentration), and were reproducible over most of the treatment occasions. Accordingly, the authors
considered that these increases are indicative of weak 2-methylpent-2-enal mutagenic activity in strain
TA100 in the absence and in the presence of S-9 in this assay system. The Panel agreed with the
authors.
The details and conclusions for the Ames tests described above are summarised in Tables D.1 and
D.3–D.6.
2.5.1.2. In vitro Micronucleus assay
2-Methylpent-2-enal [FL-no: 05.090] was evaluated in an in vitro micronucleus assay in human
peripheral blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence
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and absence of rat liver metabolic activation system (S-9) as an in vitro metabolising system (Whitwell,
2011). Cells were stimulated for 48 h with phytohaemagglutinin to produce exponential cell growth
followed by treatment for 3 h (with a 21 h recovery period) in the presence or absence of S-9 or 24 h
treatment with no recovery in the absence of S-9. In the first experiment, doses of 0, 100, 200 and
300 lg/mL of 2-methylpent-2-enal were tested. Frequencies of micronucleated binucleate (MNBN) cells
were not significantly different (p ≤ 0.05) from that of the negative control in all conditions with the
exception of the highest concentration analysed post 3 + 21 h without S-9 treatment (300.0 lg/mL,
inducing 49% cytotoxicity, mean MNBN cells 1.05%). This increase, although statistically significant
relative to the concurrent vehicle control, was relatively small and did not exceed the range of historical
controls (0.1–1.2% MNBN cells). Furthermore, both replicate cultures at this concentration and all other
2-methylpent-2-enal concentrations analysed were within a normal range of MNBN cell values.
To clarify these data, a 3 + 21 h treatment in the absence of S-9 was performed in a second
experiment with 100.0, 175.0, 260.0 and 300.0 lg/mL concentrations of 2-methylpent-2-enal.
Statistically significant increases in micronucleated cell frequencies were not observed. Consistent with
current regulatory guideline recommendations for this assay, the maximum concentrations that were
analysed induced between 49% and 57% cytotoxicity. The Panel agreed with the authors of the study
report and concluded that 2-methylpent-2-enal did not induce micronuclei in cultured human peripheral
blood lymphocytes following treatment in the absence and presence of metabolic activation with S-9
(Table D.1).
2.5.1.3. In vitro chromosomal aberration assay
The ability of 2-methylcrotonaldehyde [FL-no: 05.095] to induce chromosomal aberrations was
evaluated in an in vitro assay using Chinese hamster pulmonic fibroblasts (Nakajima, 2006b). Microscopic
observations were conducted during the chromosome aberration tests using short-term treatment with
three or four different doses respectively, 105, 210 and 421 lg/mL in the absence of S-9 and 105, 210,
421 and 841 lg/mL in the presence of S-9. The frequencies of chromosome structural aberrations as a
result of short-term treatment of 2-methylcrotonaldehyde without metabolic activation by S-9 were 0.5%
in the negative control, 3.5% in the 105 lg/mL treatment, 12.0% in the 210 lg/mL treatment, 55% in
the 421 lg/mL treatment and 50.0% in the mitomycin positive control. The appearance of polyploidy
cells was not observed at any dose and there were no significant reductions in relative cell growth rate
under these test conditions. In the presence of S-9, the frequencies of chromosome structural aberration
as a result of treatment using 2-methylcrotonaldehyde were 0.05% in the negative control, 1.5% in the
105 lg/mL dose, 1.5% in the 210 lg/mL dose, 33.0% in the 421 lg/mL dose, 96.5% in the 841 lg/mL
dose and 39% in the cyclophosphamide positive control treatment group. The frequencies of appearance
of polyploidy cells were equivalent to those of the negative control group at all doses and there was no
significant reduction in relative cell growth rate. Therefore, a dose-dependent induction of structural
chromosome aberrations was associated with 2-methylcrotonaldehyde treatment in both short-term
treatments with and without S-9 under testing conditions. An increase in numerical chromosomal
aberrations was not observed. The Panel agreed with the authors of the study report and concluded that
2-methylcrotonaldehyde induced chromosomal aberrations in cultured mammalian cells in the presence
and absence of metabolic activation (Table D.1).
2.5.2. In vivo genotoxicity tests
2.5.2.1. Micronucleus assay
2-Methylcrotonaldehyde [FL-no: 05.095] was tested in an in vivo micronucleus assay using BDF1
male mice (Nakajima, 2007). Five mice per group were administered by oral gavage with a dose of
2-methylcrotonaldehyde once per day for two consecutive days at either 250, 500 or 1,000 mg/kg bw
(1,000 mg/kg bw was the maximum tolerable dose based on an initial dose-finding study in which two
out of three animals died after administration of 2,000 mg/kg bw). The bone marrow cells were
sampled 24 h after the second dosing. Administration of 2-methylcrotonaldehyde resulted in one case
of piloerection 25 h after the first administration of 1,000 mg/kg. No other treatment groups showed
any sign of toxicity by means of visual examination or by body weight loss. There was no statistically
significant increase in the frequency of micronucleated erythrocytes in treated groups compared to the
negative control group. The ratio of polychromatic erythrocytes (PCE) among total erythrocytes was not
changed. Thus, the exposure of the bone marrow to the test substance could not be demonstrated
based on that parameter. However, since mortality was observed at a dose of 2,000 mg/kg bw in the
dose-finding study, the Panel considered that systemic availability of the test substance could be
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assumed at the highest dose of 1,000 mg/kg bw in the micronucleus assay. Although, it may be assumed
that the bone marrow was exposed to the test substance since the bone marrow is a well-perfused
tissue, no convincing evidence was provided. The Panel considered the study to be compliant with OECD
guideline 474 except that no justification for the use of a single sex was given in the report, i.e. no data
demonstrating that there are no substantial differences between sexes in toxicity. It was concluded that
2-methylcrotonaldehyde did not induce micronuclei in mice bone marrow cells (Table D.2).
2.5.3. Discussion of the additional data
2-Methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095] were tested in a
series of in vitro tests to explore their genotoxicity potential.
For 2-methylcrotonaldehyde [FL-no: 05.095], there is some evidence for a mutagenic activity in the
presence and absence of metabolic activation. This is based on two reliable studies on the induction of
bacterial gene mutations (Nakajima, 2006a; Ballantyne, 2011) with the first study providing clear
evidence for mutagenic activity and the latter study providing indication for a weak mutagenic activity.
For the representative substance 2-methylpent-2-enal [FL-no: 05.090], there is an indication for a
weak mutagenic activity both in the presence and absence of metabolic activation. This indication is
based on the results of one reliable study (Ballantyne, 2011) and structural similarity with 2-
methylcrotonaldehyde [FL-no: 05.095].
In vitro assessment of micronucleus induction by 2-methylpent-2-enal in the presence and absence
of S-9 metabolic activation was negative. In the case of 2-methylcrotonaldehyde, a dose-dependent
induction of structural, but not numerical chromosomal aberrations in vitro was observed, both with
and without S-9. To further investigate the clastogenic potential an in vivo micronucleus assay using
BDF1 male mice was performed and no evidence of clastogenic effects was identified but the
respective test was inconclusive. These data support the absence of clastogenicity for the two
substances 2-methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095].
However, since there is some evidence for 2-methylcrotonaldehyde [FL-no: 05.095] and an
indication for 2-methylpent-2-enal [FL-no: 05.090] to show a potency for the induction of gene
mutations in vitro the Panel considered the mutagenicity hazard not cleared by the endpoints
evaluated in the in vivo micronucleus assay. The Panel therefore concluded that further data are
required in order to clarify the genotoxic potential of this subgroup. The Panel considers the in vivo
Comet assay as a preferred option to further investigate the genotoxicity in vivo. The Comet assay will
also be accountable to explore any genotoxicity at the first site of contact where higher concentrations
of the test substance are expected to occur. In this view, the in vivo Comet assay should be performed
on liver, blood and first site of contact (e.g. duodenum or stomach). Alternatively, a transgenic rodent
gene mutation assay (OECD TG 488) in tissues including first site of contact would also be acceptable.
Since 2-methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095] are closely
related chemical structures, it is expected that they will have a similar reactivity behaviour. Since the
evidence for a mutagenic activity in vitro is stronger for 2-methylcrotonaldehyde [FL-no: 05.095] than
for 2-methylpent-2-enal [FL-no: 05.090], the Panel considers that additional data for the former
substance are required. A negative result of 2-methylcrotonaldehyde [FL-no: 05.095] in the in vivo
assay would be considered representative for the following substances of this subgroup [FL-no:
02.174, 05.033, 05.090, 05.105, 05.107 and 05.126]. A positive result of 2-methylcrotonaldehyde [FL-
no: 05.095] in the in vivo assay will require further testing of these six substances [FL-no: 02.174,
05.033, 05.090, 05.105, 05.107 and 05.126] in order to finalise their evaluation.
The Panel noted that the Industry has communicated that the following two substances [FL-no:
05.178 and 09.177] are not supported any more. These two substances were selected as
representative for the substances in subgroup 1.1.2 and in addition also for substances in subgroup
2.1 (FGE.207). Since no data will be provided for these substances, they cannot further be used as
representatives for the substances [FL-no: 02.122, 09.034, 09.712, 09.809] in FGE.207.
2-Methylpent-2-enal [FL-no: 05.090] was originally selected as representative for the subgroup
1.1.2 and also for the substances in subgroup 5.3 (FGE.225). Since the Panel now considers that
additional data are required for 2-methylcrotonaldehyde, these data could also be considered
representative for the substances in FGE.225 [FL-no: 12.065, 12.079].
The genotoxicity studies are summarised in Appendix D Tables from D.1 to D.6.
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2.5.4. Conclusion
Since there is some evidence for 2-methylcrotonaldehyde [FL-no: 05.095] and an indication for
2-methylpent-2-enal [FL-no: 05.090] to show a potency for the induction of gene mutations in vitro the
Panel considered the mutagenicity hazard not cleared by the endpoints evaluated in the in vivo
micronucleus assay on 2-methylcrotonaldehyde [FL-no: 05.095]. The Panel therefore concluded that
further data are required in order to clarify the genotoxic potential of this subgroup. The Panel considers
the in vivo Comet assay as a preferred option to further investigate the genotoxicity in vivo. Since the
evidence for a mutagenic activity in vitro is stronger for 2-methylcrotonaldehyde [FL-no: 05.095] than for
2-methylpent-2-enal [FL-no: 05.090], the Panel considers that additional data for 2-methylcrotonaldehyde
are required. The Panel concluded that the genotoxicity data for 2-methylcrotonaldehyde cannot be
considered representative for the remaining substances of this subgroup [FL-no: 05.130, 05.178, 09.177
and 09.931] for which it was already concluded in the previous version of this FGE that the available data
were insufficient to evaluate their genotoxicity.
The Panel noted that this conclusion will also have consequences for the read across for substances
in subgroups 2.1 and 5.3 (FGE.207 and FGE.225).
3. Assessment
3.1. Additional data evaluated by the Panel in FGE.201Rev2
New genotoxicity data have been provided for two substances, 2-methylpent-2-enal [FL-no:
05.090] and 2-methylbut-2-enal (2-methylcrotonaldehyde) [FL-no: 05.095]. In Table 2, the newly
submitted data are listed and they are summarised in Appendix E, Table E.1.
3.1.1. Stability and decomposition products
The Panel noted that in the recently provided in vivo genotoxicity study for 2-methylpent-2-enal
[FL-no: 05.090], this substance was stored under nitrogen; this, however, does not correspond to the
conditions of storage of the flavouring substances expected under normal conditions of use (i.e.
storage for 12 months at temperatures < 18°C and out of direct light and air) (EFFA, 2018 in response
to EFSA letter dated 9 August 2017, requesting information on storage conditions and chemical
stability of [FL-no: 05.090] and requesting to test [FL-no: 05.095] in an in vivo comet assay).
To decide whether the substances subjected to genotoxicity testing can be considered
representative of the materials of commerce, the Panel requested information on the stability of 2-
methylpent-2-enal [FL-no: 05.090] under its intended conditions of use. The applicant provided data
on both 2-methylpent-2-enal [FL-no: 05.090] and 2-methylcrotonaldehyde [FL-no: 05.095] from
capillary gas chromatographic analyses of freshly prepared flavouring substances and of flavouring
substances stored up to the end of their shelf-life or longer.
For 2-methylpent-2-enal [FL-no: 05.090], the purity of fresh samples was 95–> 98% (this purity
covers mainly the E-isomer that is > 90%). The main secondary component reported was: 2-methyl-2-
pentenoic acid (< 0.5% in fresh samples up to 1% in samples after storage) – mainly the (E)-2-
methyl-2-pentenoic acid was reported. The purity of samples stored up to 4 years (maximum
expiration time reported) reported was > 96% (the purity covers mainly the E-isomer) and the main
secondary components reported were (E) and (Z)-2-methyl-2-pentenoic acid (up to 1%).
For 2-methylcrotonaldehyde [FL-no: 05.095], the purity of fresh samples was 95–> 98% (this purity
covers mainly the E-isomer that is > 95%). Secondary components reported were: acetic acid (up to
0.1%), tiglic acid (up to 0.5%) and paraldehyde (up to 1%) (i.e. 2,4,6-trimethyl-1,3,5-trioxane, which
is a condensation product – cyclic ether).
Table 2: List of genotoxicity studies evaluated in FGE.201Rev2
Substance name FL-no In vivo test Reference
2-Methylpent-2-enal 05.090 Combined MN and Comet assay in liver and
duodenum of rats
Keig-Shevlin (2016)
2-Methylcrotonaldehyde 05.095 Comet in liver and duodenum of rats Bruce (2018)
Combined gene mutation and micronucleus
assay in transgenic rats
JBRC (2014, 2016)
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The purity of samples stored up to 4 years (maximum expiration time reported) reported was
95–> 96%. The composition of the secondary components was reported as follows: acetic acid
(< 0.5%), tiglic acid (up to 2%) and paraldehyde (up to 2%) (EFFA, 2018).
The Panel concluded that the materials tested in the genotoxicity studies are representative of the
material of commerce.
3.1.2. 2-Methylpent-2-enal [FL-no: 05.090] – in vivo combined micronucleus and
comet assay
The genotoxic potential of 2-methylpent-2-enal [FL-no: 05.090] (purity 99.1%, stored protected
from light under nitrogen) was assessed in vivo using the bone marrow micronucleus assay combined
with the Comet assay in liver and duodenum in the same animals (Keig-Shevlin, 2016). The study was
conducted in accordance with GLP, OECD TG 474 (OECD, 2014a) and OECD TG 489 (OECD, 2014b).
In a dose range-finder assay, groups of three male and three female Han Wistar rats were given
three administrations (at 0, 24 and 45 h) of 2-methylpent-2-enal, at 1,000, 1,400 or 2,000 mg/kg bw
per day. At 1,000 and 1,400 mg/kg bw per day, no clinical signs of toxicity were observed. At
2,000 mg/kg bw per day, clinical signs of toxicity were observed only after the third administration.
These included decreased activity, hunched posture, piloerection, lethargy, ataxia and ptosis. One
female animal was killed in extremis. All other animals were back to a normal condition by 8 hours
post-dose. Minor losses in bodyweight were observed in all three males, but no losses in bodyweight
were observed in the two remaining females. Based on this study, a maximum tolerated dose (MTD) of
1,400 mg/kg bw per day was established. As no gender specific effects were seen, only male rats
were used in the main study. Groups of six male Han Wistar rats per dose group were administered
doses by oral gavage of 0 (corn oil), 350, 700 or 1,400 mg/kg bw of 2-methylpent-2-enal on three
consecutive days (0, 24 and 45 h). A satellite group of three male rats were given the same dosing
regimen as the 1,400 mg/kg bw per day group rats. A positive control group of three male rats were
given doses of 150 mg ethyl methanesulfonate/kg bw at the same time intervals as the dosed groups.
Test animals were examined daily for signs of overt toxicity and body weights were recorded. No
changes in body weight, clinical chemistry parameters or histopathology were observed.
Rats were euthanised 3 h after the last dose and 48 h after the initial dose. Blood samples were
taken at necropsy for clinical chemistry analysis.
Comet assay
Liver and duodenum cells were prepared for Comet scoring. For both tissue types, the tail moment
and tail intensity (%) of a total of 150 cells per animal, split over two to three slides, were recorded.
Both in liver and in duodenum, there was no dose-related increase in %hedgehogs following
treatment with 2-methylpent-2-enal demonstrating that treatment did not cause excessive DNA
damage that could have interfered with Comet analysis.
In liver, no statistically significant increase in group mean tail intensity and tail moment values was
seen in any test substance treatment group compared to the vehicle control treatment group. However, a
weak but statistically significant linear trend (p < 0.05) was observed. Although the data did not meet the
criteria for a clearly negative result, the increases in tail intensity were minor, not statistically significant
and fell at the lower end of the historical vehicle control range for tail intensity (0.08–5.08). Therefore, the
data were considered to be within the usual variation seen in this assay and of no biological relevance.
The positive control provided statistically significant increases in both tail intensity and tail moment.
In duodenum, there were no dose-related increases in the tail intensity or tail moment and no
statistically significant results compared to the control group. The positive control provided statistically
significant increases in both tail intensity and tail moment.
Micronucleus assay
Bone marrow from the femurs was prepared for micronucleus scoring. A total of at least 500 PCE
and normochromatic erythrocytes (NCE) was scored to calculate the degree of bone marrow toxicity
by the relative decrease in PCE. For micronuclei (MN) analysis, 4,000 PCE per animal were scored for
the presence of MN. In order to improve data interpretation, additional 4,000 PCE were analysed to a
total of 8,000 PCE per animal.
2-Methylpent-2-enal [FL-no: 05.090] did not induce micronuclei in bone marrow of rats tested up to
1,400 mg/kg bw per day (MTD). No indication of bone marrow toxicity was observed, because the
treatment with 2-methylpent-2-enal [FL-no: 05.090] did not reduce the percentage of PCE. However,
Flavouring Group Evaluation 201 Revision 2
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2018;16(10):5423
in the range-finding test, at 2,000 mg/kg bw per day (above the MTD), clinical signs of toxicity were
observed (including decreased activity, hunched posture, lethargy, ataxia) that could be considered as
a line of evidence of systemic exposure.
In the same animals, 2-methylpent-2-enal [FL-no: 05.090] showed negative results in the comet
assay both in duodenum and liver. The Panel concluded that 2-methylpent-2-enal [FL-no: 05.090] did
not induce DNA damage under the conditions of this study.
3.1.3. 2-Methylcrotonaldehyde [FL-no: 05.095] – in vivo combined gene
mutation and micronucleus assay in transgenic rats
2-Methylcrotonaldehyde [FL-no: 05.095] (purity 99.5%) was tested in a combined gene mutation and
micronucleus assay in transgenic Fisher gpt delta rats. Liver and glandular stomach were analysed for gene
mutation and peripheral blood erythrocytes for micronuclei (JBRC, 2014 and additional assay 2016). The
study was performed in accordance with OECD TG 488 (OECD, 2013) and OECD TG 474 (OECD, 1997).
In a dose range-finding 14-day test, a MTD of 500 mg/kg bw per day was established, based on
the observation that one out of three animals died in the 1,000 mg/kg bw per day dose group. In the
main study, groups of six transgenic rats were administered 2-methylcrotonaldehyde, by gavage, daily
doses of 0, 125, 250 and 500 mg/kg bw per day for 28 days. The solvent, olive oil, was the negative
control. As a positive control, one group of six rats was given a single i.p. dose of 125 mg/kg bw of
benzo[a]pyrene (B[a]P).
Besides clinical observations of lacrimation and salivation found in some animals in the 250 and
500 mg/kg bw per day groups, no other clear toxicity effects from the test substance were found for
body weight, food consumption, gross findings, liver weight, and histopathological lesions of the liver,
bone marrow, spleen, stomach, small intestine and large intestine.
Livers from the positive control group were removed 7 days after the treatment. In animals of the
other groups, liver and glandular stomach were removed 3 days after the treatment. While liver was
analysed immediately for gene mutations (JBRC, 2014), glandular stomach was analysed for gene
mutations at a later stage (JBRC, 2016).
For glandular stomach, no positive control was included, but the authors used the results of
positive control (B[a]P)in liver. The OECD TG 488 does not provide any suggestion for a positive
control to be used in the mutation assay of rat’s stomach.
Twenty-four hours after the final dose had been given, blood samples from the tail vein of treated
rats were collected for scoring of micronuclei in the immature erythrocytes, and after a manifestation
period of 3 days, rats were euthanised.
No historical control data for the performing laboratory were included in the study report but
reference was made to published papers.
Gene mutation assay
Genomic DNA was extracted from liver and glandular stomach of treated rats. The isolated gpt
transgene sequences were packaged into a lambda phage shuttle vector and mutations subsequently
detected in E. coli YG6020 (6TG selection) and in E. coli XL-1Blue MRA (Spi selection).
There were no increases in gpt and Spi mutant frequencies in the liver of the transgenic rats
following treatment with 2-methylcrotonaldheyde compared to the negative control whereas significant
increases were seen in the positive control, B[a]P (JBRC, 2014).
There were no increases in gpt and Spi mutant frequencies in the glandular stomach of transgenic
rats following treatment with 2-methylcrotonaldehyde compared to the negative control. No positive
control was included in the study for the effect in the glandular stomach (JBRC, 2016).
Micronucleus assay
For each slide, 2,000 PCE were scored for MN.
No increases in micronucleated immature erythrocytes in the peripheral blood were observed in the
2-methylcrotonaldehyde treated groups compared to the negative control, while a statistically
significant increase was seen in the positive control group.
Based on these results, the authors of the study concluded that 2-methylcrotonaldehyde is not
mutagenic in the liver nor in the glandular stomach of gpt delta transgenic rats and does not induce
micronuclei in the peripheral blood of the same rats.
The Panel noted that there are no indications of bone marrow toxicity because the percentage of
PCE is not affected by the treatment with 2-methylcrotonalheyde. In addition, there are no indications
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of bone marrow exposure based on the clinical signs of toxicity observed, therefore the micronucleus
assay is inconclusive. Since the potential clastogenicity of [FL-no: 05.095] is not clarified in this study,
it was requested to test [FL-no: 05.095] in an in vivo comet assay (EFSA letter dated 9 August 2017).
The Panel concluded that 2-methylcrotonaldheyde did not induce gene mutations in the liver and the
glandular stomach under the conditions applied in this study.
3.1.4. 2-Methylcrotonaldehyde [FL-no: 05.095] - in vivo comet assay
2-Methylcrotonaldehyde [FL-no: 05.095] (purity ≥ 99%) was tested in a comet assay in liver and
duodenum of male Sprague–Dawley rats (Bruce, 2018), in accordance with OECD TG 489 (OECD, 2016)
and GLP. Animals were dosed via oral gavage on two consecutive days, the second dose was administered
21 hours after the first dose. The vehicle control used was corn oil and the positive control was ethyl
methanesulfonate (EMS). Animals were dosed once with EMS, 3–4 h before euthanasia on day 2.
No dose range-finding experiment was performed. 2-Methylcrotonaldehyde was tested at 250, 500,
1,000 and 2,000 mg/kg bw per day (six animals per group). At the highest dose tested, three animals
were found dead. In the surviving animals, reductions in mean group body weights were observed in
the 2,000 mg/kg bw per day group.
At 250 and 500 mg/kg bw per day, no clinical signs of toxicity were observed except piloerection at
500 mg/kg bw per day. At 1,000 and 2,000 mg/kg bw per day, clinical signs of toxicity, including
piloerection, ataxia, prostration, irregular breathing, hunched position, were observed.
Due to the elevated mortality (3 animals out of six) occurred in the highest treatment group
(2,000 mg/kg bw per day) the remaining animals were excluded from the Comet analysis.
For both liver and duodenum, the comet assay resulted in no dose-dependent or statistically
significant increases in the % tail DNA in animals dosed with 2-methylcrotonaldehyde up to and
including a dose of 1,000 mg/kg bw per day, compared to the concurrent vehicle control group.
In liver and duodenum cells, the positive control, EMS, induced a statistically significant increase in
the % tail DNA as compared to the vehicle control groups (p ≤ 0.05). In the vehicle control group, %
tail DNA was within the historical vehicle control range respectively for liver and duodenum.
The authors of the study concluded that under the conditions of this study, 2-methylcrotonaldehyde
did not induce DNA damage in liver and duodenum of rats. The Panel agreed with this conclusion.
3.2. Discussion
In FGE.201Rev1, the Panel considered that for 2-methylpent-2-enal [FL-no: 05.090] there was an
indication for a weak mutagenic activity in bacteria both in the presence and absence of metabolic
activation. In vitro assessment of micronucleus induction by 2-methylpent-2-enal [FL-no: 05.090] in
the presence and absence of S9 metabolic activation was negative.
In FGE.201Rev1, the Panel considered that for 2-methylcrotonaldehyde [FL-no: 05.095] there is
some evidence for a mutagenic activity in bacteria in the presence and absence of metabolic
activation. In addition, a dose-dependent induction of structural chromosomal aberrations in vitro was
observed, both with and without S9-mix. The in vivo micronucleus assay on 2-methylcrotonaldehyde
[FL-no: 05.095] was not sufficient to overrule the genotoxicity concern; therefore, additional
genotoxicity data have been provided that are evaluated in the present revision, FGE.201Rev2.
2-Methylpent-2-enal [FL-no: 05.090] tested in a combined micronucleus and comet assay did not
induce DNA damage, overruling the weak gene mutation effect observed in bacteria and confirming
the negative results observed in the in vitro micronucleus assay.
2-Methylcrotonaldehyde [FL-no: 05.095] did not induce gene mutations in vivo in liver and
glandular stomach of transgenic rats (gpt and Spi- assay). In addition, 2-methylcrotonaldehyde [FL-no:
05.095] tested in an in vivo comet assay in liver and duodenum, it did not induce DNA damage.
The extrapolation from two representative substances to eight candidate substances is intrinsically
associated with the introduction of uncertainty. In this opinion, only one toxicological endpoint is
addressed (genotoxicity) related to one well defined structural alert, therefore the uncertainty is
considered to be limited. Other toxicological endpoints will be addressed in separate opinions.
3.3. Conclusion
Overall, based on the data obtained the Panel concluded that the genotoxic evidence observed
in vitro, was not confirmed in vivo. Since the genotoxicity concern is cleared for the representative
substances 2-methylcrotonaldehyde [FL-no: 05.095] and 2-methylpent-2-enal [FL-no: 05.090], all the
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ten substances in this subgroup [FL-no: 02.174, 05.033, 05.090, 05.095, 05.105, 05.107, 05.126,
07.261, 12.065 and 12.079] can be evaluated through the Procedure for the evaluation of flavouring
substances.
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bw body weight
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHL Chinese hamster lung (cells)
CHO Chinese hamster ovary (cells)
CoE Council of Europe
DTU-NFI Danish Technical University – National Food Institute
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EMS ethyl methanesulfonate
FAO Food and Agriculture Organization of the United Nations
FAF Panel on Food Additives and Flavourings
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)




ISS Istituto Superiore di Sanita
JECFA Joint FAO/WHO Expert Committee on Food Additives
MN micronuclei
MNBN micronucleated binucleate cells
MS mass spectrometry
MTD maximum Tolerated Dose
MSDI maximised Survey-derived Daily Intake
NCE normochromatic erythrocytes
NMR nuclear magnetic resonance
No Number
OECD Organisation for Economic Co-operation and Development
PCE polychromatic erythrocytes
(Q)SAR (Quantitative) Structure–Activity Relationship
WHO World Health Organization
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Appendix A – Specification Summary of the Substances in the Flavouring Group Evaluation 201Rev2

















































































Mainly E-isomer (> 90%).
Secondary components (E)
and (Z)-2-methyl-2-pentenoic
acid (< 0.5% in fresh






















Mainly E-isomer (> 95%).
Secondary components: acetic
acid (up to 0.1%), tiglic acid
(up to 0.5%) and paraldehyde
(up to 1%) (i.e. 2,4,6-
trimethyl-1,3,5-trioxane,
which is a condensation
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FL-no: FLAVIS number; JECFA: Joint FAO/WHO Expert Committee on Food Additives; FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract Service;
ID: Identity; NMR: nuclear magnetic resonance; IR: infrared; MS: mass spectrometry.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1,013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
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Appendix B – Summary of safety evaluation applying the procedure





















2-Methylbut-2-en-1-ol OH 0.037 Class I
A3: Intake below
threshold
(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.










(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.










(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.










(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.








(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.











(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.










(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.
The substance can be evaluated through the Procedure
05.130 alpha-Sinensal O Not evaluated by
JECFA












– Not evaluated by
JECFA
Evaluated in FGE.201Rev2 as of no genotoxicity concern.
The substance can be evaluated through the Procedure
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(d) Evaluated in FGE.207, as of no genotoxicity concern and












(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.













(d) Evaluated in FGE.201Rev2 as of no genotoxicity concern.
The substance can be evaluated through the Procedure
ND: not determined; JECFA: The Joint FAO/WHO Expert Committee on Food Additives; FL-no: FLAVIS number; MSDI: maximised survey-derived daily intake; FGE: Flavouring Group Evaluation.
(a): EU MSDI: Amount added to food as flavour in (kg/year) 9 10E9/(0.1 9 population in Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita per day.
(b): Thresholds of concern: Class I = 1,800 lg/person/day, Class II = 540 lg/person/day, Class III = 90 lg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
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Appendix C – (Q)SAR predictions





































































NEG NEG NEG NEG NEG
05.130 alpha-Sinensal O 3141
10380
17909-77-2














NYA POS OD OD OD
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NYA NEG OD NEG NEG
FEMA: Flavor and Extract Manufacturers Association; CoE: Council of Europe; CAS: Chemical Abstract Service;
(a): Structure group 1.1.2: Aliphatic acyclic a,b-unsaturated 2-alkylated aldehydes.
(b): Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD: out of domain; NYA: not yet assessed).
(c): MultiCase Ames test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
(d): MultiCase Mouse Lymphoma test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
(e): MultiCase Chromosomal aberration in CHO (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
(f): MultiCase Chromosomal aberration in CHL (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal).
OD, out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physicochemical, structural, biological, etc.
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Appendix D – Genotoxicity data evaluated in FGE.201Rev1
In vitro studies available for the group of aldehydes and the aldehydes anticipated to be formed from the precursors in subgroup 1.1.2.
Table D.1: Genotoxicity studies in vitro
Chemical Name
[FL-no]








Negative(a) Florin et al.
(1980)
Insufficient validity (spot test,
not according to OECD





1.6, 8, 40, 200, 1,000
and 5,000 lg/plate
Negative(a),(c) Bowen (2011) (d)Valid. The study was
performed in compliance with
GLP and according to OECD TG
471
78.13, 156.13, 312.5,













(g)Valid. The study was
performed in compliance with
GLP and according to OECD TG
471 except that only one
bacterial strain was used51.2, 128, 320, 800,




8.192, 20.48, 51.2, 128,






51.2, 128, 320, 800,








100, 200 and 300 lg/ml Negative(e),(j) Whitwell
(2011)
(k)Valid. The study was
performed in compliance with
GLP and according to OECD TG
487
200, 275 and 350 lg/ml Negative(i),(j)
20, 50, 70 and 80 lg/ml
100, 175, 260 and 300
Negative(e),(l)
Negative(c),(j)
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Chemical Name
[FL-no]
Test system Test object Concentration Reported Result Reference Comments(b)
2-methylacrolein
2-Methyl-2-propenal







Valid. Positive both with and
without S9-mix. Toxic at 1 lmol/
plate and above (S9) and









8.19, 20.5, 51.2, 128,




(m)Valid. According to the study
report, the study was performed
in compliance with Japanese
GLP standards. The study report
contained a certificate of
reliability but no details of
inspection. The study is in
accordance with OECD except
that only two plates were used
per concentration. No statistics
performed.
156, 313, 625, 1,250,




E. coli WP2uvrA 156, 313, 625, 1,250,










(n)Valid. The study was
performed in compliance with
GLP and according to OECD TG
471 except that only one
bacterial strain was used
51.2, 128, 320, 800,




8.192, 20.48, 51.2, 128,




0.32, 1.6, 8, 40, 200,








105, 210 and 421 lg/mL
without S-9 treatment
and 105, 210, 421 and




(o)Valid. According to the study
report, the study was performed
in compliance with Japanese
GLP standards. The study report
contained a certificate of
reliability but no details of
inspection. Mainly in accordance
with OECD TG 473
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One in vivo study is available for the group of aldehydes and the aldehydes anticipated to be formed from the precursors in subgroup 1.1.2.
(a): With and without metabolic activation.
(b): Validity of genotoxicity studies:
Valid.
Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or limited documentation).
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate/not validated test system).
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language).
(c): Plate incorporation method.
(d): Toxicity was observed in TA1537 at 5,000 lg/plate in the presence of S-9 and in TA102 at 1,000 lg/plate and above in the presence of S-9.
(e): Without S9 metabolic activation.
(f): Toxicity was observed in all strains in the presence of S-9 above 2,500 lg/plate and 1,250 lg/plate in TA1537. Study design complied with current recommendations. Acceptable top
concentrations were achieved.
(g): Throughout experiments some small but statistically significant increases were seen but these were attributed to normal biological variability, and were generally less than 2-fold over
concurrent vehicle controls.
(h): Pre-incubation method.
(i): With S9 metabolic activation.
(j): 3-hours incubation with 21-hours recovery period.
(k): Complies with draft OECD guideline 487. Acceptable levels of cytotoxicity were achieved at the top concentrations used in all parts of the study.
(l): 24-hours incubation with no recovery period.
(m): Study design complied with current recommendations. Acceptable top concentrations were achieved.
(n): Throughout experiments some small but statistically significant increases were generally less than 2-fold over concurrent vehicle controls.
(o): Dose-dependent increase in induction of structural chromosomal aberrations with and without S-9 treatment. No changes in numerical chromosomal aberrations were observed.
Table D.2: Genotoxicity studies in vivo evaluated in FGE.201Rev1
Chemical Name
[FL-no]











250, 500 and 1,000




Valid. According to the study report, the study was performed
in compliance with Japanese GLP standards. The study report
contained a certificate of reliability but no details of inspection.
The Panel considered the study to be compliant with OECD
guideline 474 except that no justification for the use of a single
sex was given in the report, i.e. no data demonstrating that
there are no substantial differences between sexes in toxicity
bw: body weight; GLP: Good Laboratory Practice.
(a): Validity of the genotoxicity studies:
Valid.
Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or limited documentation).
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate/not validated test system).
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language).
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Table D.3: Ames test with 2-methyl-2-butenal [05.095]
(Nakajima, 2006a) Non-toxic effects

































Positive in TA 100

































Positive in TA 100





Two plates were used per concentration. No examinations using statistical procedures were conducted.
> HC: above historical control; < HC: within historical control.
d-r: dose-related; (d-r), not clearly dose-related but the highest dose resulted in the largest increase, not d-r, not dose-related.
Pre: Pre-incubation assay.
Table D.4: Ames test with 2-methylpent-2-enal [05.090] (Bowen, 2011)
Statistically significant increases, non-toxic effects
S9 Assay TA98 TA100 TA1535 TA1537 TA102 Conclusion








Experiment 1  Plate NS NS NS NS NS Negative
+ Plate NS 1.2-fold
< HC
not d-r
NS NS NS Negative
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Table D.5: Ames test with TA100 (Ballantyne, 2011) Statistically significant increases not accompanied by toxicity
Register name
[FL-no]


















































> HC: above historical control; < HC: within historical control.
NS: statistically not significant.
d-r: dose-related but only the highest dose statistically significant; D-R, dose-related and at least two doses statistically significant.
S9 Assay TA98 TA100 TA1535 TA1537 TA102 Conclusion











> HC: above historical control; < HC: within historical control.
NS: statistically not significant.
d-r: dose-related but only the highest dose statistically significant; D-R, dose-related and at least two doses statistically significant.
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Ballantyne (2011) Comment Conclusion
2-Methylcrotonaldehyde
[05.095]
 Positive Indication for a weak
mutagenic activity
At least the indication is reproducible Indication for a mutagenic activity
based on two studies
+ Positive Indication for a weak
mutagenic activity
At least the indication is reproducible Indication for a mutagenic activity
based on two studies
2-Methylpent-2-enal
[05.090]
 Negative Indication for a weak
mutagenic activity
The indication was not reproducible
in different studies. Inconsistent results
Indication for a weak mutagenic
activity based on the results of one
study and structural similarity with
2-methylcrotonaldehyde [FL-no: 05.095]
+ Negative Indication for a weak
mutagenic activity
The indication was not reproducible
in different studies. Inconsistent results
Indication for a weak mutagenic activity
based on the results of one study and
structural similarity with
2-methylcrotonaldehyde [FL-no: 05.095]
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Appendix E – Genotoxicity studies evaluated in FGE.201Rev2
Table E.1: Summary of additional genotoxicity data submitted for FGE.201Rev2 in vivo





05.090 2-Methylpent-2-enal Comet (liver and duodenum) Han Wistar rats
Oral gavage







Micronucleus (bone marrow) Negative Study performed in
accordance with
OECD TG 474
05.095 2-Methylbut-2-enal Micronucleus (peripheral
blood erythrocytes)
Fisher gpt delta rats
Oral gavage
0 (olive oil), 125,
250 and 500
Negative JBRC (2014) The study was
performed in 2014















Comet (liver and duodenum) Sprague-Dawley rats
Oral gavage
0 (corn oil), 250,
500, 1,000 and 2,000
Negative Bruce (2018) Study performed in
accordance with
OECD TG 489
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